Parkman Healthcare Partners LLC Boosts Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 765,453 shares of the company’s stock after buying an additional 10,209 shares during the period. Kiniksa Pharmaceuticals accounts for 2.0% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 16th biggest position. Parkman Healthcare Partners LLC owned approximately 1.06% of Kiniksa Pharmaceuticals worth $15,141,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in KNSA. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $158,000. Bellevue Group AG purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $160,000. Tower Research Capital LLC TRC lifted its stake in shares of Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after buying an additional 4,575 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

KNSA has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Finally, Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $38.80.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, insider Ross Moat sold 18,259 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares of the company’s stock, valued at approximately $191,030.35. This represents a 65.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares in the company, valued at $595,553.60. This represents a 25.44% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 228,768 shares of company stock worth $5,591,506. 54.57% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Stock Down 4.6%

KNSA stock opened at $25.60 on Wednesday. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -182.84 and a beta of 0.07. The business has a fifty day simple moving average of $22.60 and a 200-day simple moving average of $21.32. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $17.38 and a 52 week high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.25) earnings per share. As a group, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.